相关实验视频

Updated: Jul 6, 2026

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
06:34

A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation

Published on: March 27, 2017

12.0K

使用临床主张数据库评估beta2-微球蛋白吸附对透析相关的粉症的治疗效果

Chikao Onogi, Akihito Tanaka, Kazuhiro Furuhashi

    Blood purification
    |August 28, 2025
    PubMed
    概括

    在血液透析患者中,β2- 微球蛋白 (β2MG) 吸附列可能有助于减缓透析相关的粉症 (DRA) 的进展. 虽然没有统计学意义,但治疗显示了手腕道或触发指释放的重新手术率下降的趋势.

    更多相关视频

    Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia07:18

    Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

    Published on: November 9, 2018

    8.5K
    Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

    Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

    Published on: November 10, 2021

    1.9K

    相关概念视频

    Therapeutic Drug Monitoring: Affecting Factors01:29

    Therapeutic Drug Monitoring: Affecting Factors

    Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.